Antibody Details
Product Details
Reactivity Species
Baboon
⋅
Chimpanzee
⋅
Cynomolgus Monkey
⋅
Feline
⋅
Bovine
⋅
Human
Host Species
Mouse
Immunogen
Human tonsil cell membrane
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
⋅
> 95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
This antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at – 20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
2-8°C
RRID
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this HLA-A, B, C Clone W6/32 antibody for staining cells in flow cytometry is ≤ 2.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for for use in western blotting is 1-10 μg/ml.
Other Applications Reported In Literature ?
B
CODEX®
IHC FF
IP
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Description
Specificity
Clone W6/32 recognizes the human MHC class I molecules HLA-A, -B, and -C.
Antigen Distribution
HLA-A, -B, and -C are ubiquitously expressed on nucleated cells.
Background
HLA antibody, clone W6/32, recognizes the major histocompatibility complex (MHC) class I molecules human leukocyte antigen (HLA)-A, HLA-B, and HLA-C. MHC class I is ubiquitously expressed on the cell surface of nucleated cells and consists of a 45-kDa type I transmembrane glycoprotein (α-chain or heavy chain) and a 12-kDa soluble protein (β2-microglobulin, β2M)1, 2. The α-chain consists of three domains (α1, α2, and α3)3. α1 and α2 form the closed antigen-binding groove and bind to 8-10 aa peptides derived from cytosolic antigens4-6. β2M noncovalently associates with α3, which is essential for MHC stability. MHC class I plays a critical role in the adaptive immune response by presenting endogenous antigens to cytotoxic CD8 T cells. MHC class I molecules can also present exogenous antigens to CD8 T cells via a process known as cross-presentation7. The T cell receptor (TCR)/CD3 complex of CD8 T cells interacts with peptide-MHC class I, which induces CD8 T cell activation and subsequent cell-killing. CD8 molecules also bind to MHC class I, which helps augment TCR signaling8. In contrast to CD8 T cells, MHC class I is an inhibitory ligand for natural killer (NK) cells, promoting self tolerance9. MHC class I also contributes to the positive selection of CD8 T cells and NK cell specificity10, 11.
Antigen Details
Protein
HLA-A, B, C
Ligand/Receptor
CD3/TCR, CD8
Function
Antigen presentation
PubMed
HLA-A, B, C
NCBI Gene Bank ID
3105
UniProt.org
Information on Uniprot.org
Research Area
Immunology
.
Innate Immunity
References & Citations
1. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25
2. Wieczorek M, et al. (2017) Front Immunol. 8:292
3. Jones EY. (1997) Curr Opin Immunol. 9(1):75-9
4. Matsumura M, et al. (1992) Science. 257:927–34.10.1126/science.1323878
5. Bouvier M & Wiley DC. (1994) Science. 265:398–402.10.1126/science.8023162
6. Zacharias M & Springer S. (2004) Biophys J. 87:2203–14.10.1529/biophysj.104.044743
7. Cruz FM, et al (2017) Annu Rev Immunol. 35:149-176
8. Artyomov MN, et al (2010) Proc Natl Acad Sci USA. 107(39):16916-16921
9. Orr MT & Lanier LL. (2010) Cell. 142(6):847-856
10. Raulet DH. (1994) Adv Immunol. 55:381-421
11. Salcedo M & Ljunggren HG. (1996) Chem Immunol. 64:44-58
Technical Protocols